Clinical Trial Update: Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Pfizer withdrew a Phase 3 trial evaluating CP-751,871 in combination with gemcitabine and cisplatin for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)
• Gemzar (gemcitabine)
• Platinol (cisplatin)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: WITHDRAWN